Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound Duzhong Jiangu Granules (Fufang Duzhong Jiangu Keli) is a Traditional Chinese Medicine (TCM) formulation primarily used for the treatment of knee osteoarthritis (KOA). Developed or studied by The Third Affiliated Hospital of Beijing University of Chinese Medicine, it is typically composed of several herbal ingredients, with *Eucommia ulmoides* (Duzhong) as a key component. The formulation is designed to strengthen bones and tendons, alleviate pain, and improve joint function. It is currently being evaluated in real-world registry studies in China to assess its effectiveness and safety both as a monotherapy and in combination with conventional treatments for KOA.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Compound Duzhong Jiangu Granules.